The “black box” warning on the popular diabetes and weight loss drug semaglutide may be shifting from a cautionary black to a reassuring grey. A landmark study published in The Journal of Clinical Endocrinology & Metabolism reveals that semaglutide does not promote thyroid cancer; instead, it may suppress tumor growth by “reprogramming” the immune system...
Eli Lilly’s “Ozempic-in-a-pill” candidate just cleared its most significant clinical hurdle to date. The pharmaceutical giant announced that its experimental once-daily pill, orforglipron, met all primary and secondary endpoints in two pivotal Phase 3 trials: ACHIEVE-2 and ACHIEVE-5. Data indicate that this oral treatment provides superior glycemic control compared to both a standard SGLT-2 inhibitor...
The Endocrine Society is pleased to announce its Rare Endocrine Disease (RED) Fellows Program, a series designed to equip early-career physicians with the knowledge and practical skills needed to improve outcomes for people living with rare endocrine diseases. The program was developed in partnership with the National Organization for Rare Disorders (NORD) and addresses critical gaps in awareness, diagnosis and care of rare endocrine diseases. The program consists of two core components: The program accepts up...
A new year brings a new therapeutic milestone for weight management: Following its recent U.S. Food and Drug Administration approval, the 25 mg oral semaglutide tablet (brand name: Wegovy), a once-daily pill became available in the United States in early January 2026 for chronic weight management and for reducing the risk of major adverse cardiovascular...
As we leave 2025 behind and look forward to the new year ahead, what better way to kick off 2026 than with a multi-page tribute to the latest class of Endocrine Society Laureate Award winners? In “Meet the 2026 Laureates,” we feature this year’s stellar array of legends of endocrinology from around the world. This...
As this article went to press, Congress has yet to complete a full-year spending bill for the current fiscal year (FY 2026) to fund the National Institutes of Health (NIH). This ongoing uncertainty has impacted NIH’s ability to award grants, with consequences for our member scientists and their work. Meanwhile, the Trump administration aims to release their...
Nicknamed the “butterfly gland” due to its shape, the thyroid’s impact on the body is far reaching. Usually associated with growth and metabolism, recent studies published in The Journal of Clinical Endocrinology & Metabolism – Case Reports show how thyroid dysfunction can impact the heart. The common phrase “heart in my throat” usually refers to...
A woman’s insulin levels in midlife are linked to the timing and duration of menopausal hot flashes, night sweats and cold sweats, according to new research from the University of Victoria (UVic). The study found that having higher insulin levels at age 47 predicted younger onsets of hot flashes and night sweats,” says Faria Athar, lead author...
As we leave 2025 behind and look forward to the new year ahead, what better way to kick off 2026 than with a multi-page tribute to the latest class of Endocrine Society Laureate Award winners? In “Meet the 2026 Laureates,” we feature this year’s stellar array of legends of endocrinology from around the world. This...
